GDRX•benzinga•
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst
Summary
J.P. Morgan analyst revises outlook on GoodRx Holdings following Q1 earnings, reaffirms Overweight rating and $7 price target.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 19, 2025 by benzinga